HOHiroko Ohgaki

Hiroko Ohgaki

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Hiroko Ohgaki has a total of 199 co-authors. Here are the top co-authors by number of shared publications:

  • Paul Kleihues

    Faculty of Medicine, University of Zurich, Zurich, Switzerland

    30 shared publications
  • Michel Mittelbronn

    Institute of Neurology (Edinger Institute), Goethe-University, Frankfurt/Main, Germany

    12 shared publications
  • Yasuhiro Yonekawa

    University Hospital Zürich

    12 shared publications
  • Anne Vital

    Bordeaux Institute of Neuroscience, CNRS UMR 5293, F-33076, Bordeaux, France

    10 shared publications
  • Werner Paulus

    Institute of Neuropathology, University Hospital Münster, D-48149, Münster, Germany

    9 shared publications
  • Young-Ho Kim

    International Agency for Research on Cancer , INSERM, Lyon, France Translational Epidemiology Research Branch, National Cancer Center , Goyang, Republic of Korea

    8 shared publications

Latest Publications

  • Open Access

    CASP9 germline mutation in a family with multiple brain tumors

    by Michael W. Ronellenfitsch, Ji‐Eun Oh, Kaishi Satomi, Koichiro Sumi, Patrick N. Harter, Joachim P. Steinbach, Jörg Felsberg, David Capper, Catherine Voegele, Geoffroy Durand, et al.

    We report a novel CASP9 germline mutation that may increase susceptibility to the development of brain tumors. We identified this mutation in a family in which three brain tumors had developed within three generations, including two anaplastic astrocytomas occurring in cousins. The cousins were diagnosed at similar ages (29 and 31 years), and their tumors showed similar histological features. Genetic analysis revealed somatic IDH1 and TP53 mutations in both tumors. However, no germline TP53 mutations were detected, despite the fact that this family fulfills the criteria of Li–Fraumeni‐like syndrome. Whole exome sequencing revealed a germline stop‐gain mutation (R65X) in the CASP9 gene, which encodes caspase‐9, a key molecule for the p53‐dependent mitochondrial death pathway. This mutation was also detected in DNA extracted from blood samples from the two siblings who were each a parent of one of the affected cousins. Caspase‐9 immunohistochemistry showed the absence of caspase‐9 immunoreactivity in the anaplastic astrocytomas and normal brain tissues of the cousins. These observations suggest that CASP9 germline mutations may have played a role at least in part to the susceptibility of development of gliomas in this Li–Fraumeni‐like family lacking a TP53 germline mutation.


  • Braf Mutations Initiate the Development of Rat Gliomas Induced by Postnatal Exposure to N-Ethyl-N-Nitrosourea

    by Qi Wang, Kaishi Satomi, Ji Eun Oh, Barbara Hutter, Benedikt Brors, Nicolle Diessl, Hai-Kun Liu, Stephan Wolf, Otmar Wiestler, Paul Kleihues, et al.


  • Open Access

    Genetic Alterations in Gliosarcoma and Giant Cell Glioblastoma

    by Ji Eun Oh, Takashi Ohta, Naosuke Nonoguchi, Kaishi Satomi, David Capper, Daniela Pierscianek, Ulrich Sure, Anne Vital, Werner Paulus, Michel Mittelbronn, et al.

    The majority of glioblastomas develop rapidly with a short clinical history (primary glioblastoma IDH wild‐type), whereas secondary glioblastomas progress from diffuse astrocytoma or anaplastic astrocytoma. IDH mutations are the genetic hallmark of secondary glioblastomas. Gliosarcomas and giant cell glioblastomas are rare histological glioblastoma variants, which usually develop rapidly. We determined the genetic patterns of 36 gliosarcomas and 19 giant cell glioblastomas. IDH1 and IDH2 mutations were absent in all 36 gliosarcomas and in 18 of 19 giant cell glioblastomas analyzed, indicating that they are histological variants of primary glioblastoma. Furthermore, LOH 10q (88%) and TERT promoter mutations (83%) were frequent in gliosarcomas. Copy number profiling using the 450k methylome array in 5 gliosarcomas revealed CDKN2A homozygous deletion (3 cases), trisomy chromosome 7 (2 cases), and monosomy chromosome 10 (2 cases). Giant cell glioblastomas had LOH 10q in 50% and LOH 19q in 42% of cases. ATRX loss was detected immunohistochemically in 19% of giant cell glioblastomas, but absent in 17 gliosarcomas. These and previous results suggest that gliosarcomas are a variant of, and genetically similar to, primary glioblastomas, except for a lack of EGFR amplification, while giant cell glioblastoma occupies a hybrid position between primary and secondary glioblastomas.


  • Open Access

    Alterations in the NF2/LATS1/LATS2/YAP Pathway in Schwannomas

    by Ji-Eun Oh, Takashi Ohta, Kaishi Satomi, Matthieu Foll, Geoffroy Durand, James McKay, Florence Le Calvez-Kelm, Michel Mittelbronn, Benjamin Brokinkel, Werner Paulus, et al.

    Schwannomas are benign nerve sheath tumors composed of well-differentiated Schwann cells. Other than frequent NF2 (neurofibromatosis type 2) mutatio


  • Open Access

    Alterations of theRRASandERCC1Genes at 19q13 in Gemistocytic Astrocytomas

    by Takashi Ohta, Young-Ho Kim, Ji-Eun Oh, Kaishi Satomi, Naosuke Nonoguchi, Kathy Keyvani, Daniela Pierscianek, Ulrich Sure, Michel Mittelbronn, Werner Paulus, et al.

    Gemistocytic astrocytoma (World Health Organization grade II) is a rare variant of diffuse astrocytoma that is characterized by the presence of neopl


  • TP53, MSH4, and LATS1 Germline Mutations in a Family with Clustering of Nervous System Tumors

    by Young-Ho Kim, Takashi Ohta, Ji Eun Oh, Florence Le Calvez-Kelm, James McKay, Catherine Voegele, Geoffroy Durand, Michel Mittelbronn, Paul Kleihues, Werner Paulus, et al.


  • Open Access

    Definition of Primary and Secondary Glioblastoma—Response

    by Hiroko Ohgaki, Peter Burger, Paul Kleihues

    We thank Dr. Barthel and colleagues for taking an interest in our review on primary and secondary glioblastoma ([1][1]). They present the case of a 72-year-old patient with an IDH1 mutation–negative glioblastoma, monitored by combined [11C]methionine (MET) amino acid transport PET/MRI. They


  • TERT promoter mutations in primary and secondary glioblastomas

    by Naosuke Nonoguchi, Takashi Ohta, Ji-Eun Oh, Young-Ho Kim, Paul Kleihues, Hiroko Ohgaki

    Telomerase reverse transcriptase (TERT) is up-regulated in a variety of human neoplasms. Mutations in the core promoter region of the TERT gene, which increases promoter activity, have been reported in melanomas and a variety of human neoplasms, including gliomas. In the present study, we screened for TERT promoter mutations by direct DNA sequencing in a population-based collection of 358 glioblastomas. TERT promoter mutations (C228T, C250T) were detected in 55 % glioblastomas analysed. Of these, 73 % had a C228T mutation, and 27 % had a C250T mutation; only one glioblastoma had both C228T and C250T mutations. TERT promoter mutations were significantly more frequent in primary (IDH1 wild-type) glioblastomas (187/322; 58 %) than in secondary (IDH1 mutated) glioblastomas (10/36, 28 %; P = 0.0056). They showed significant inverse correlations with IDH1 mutations (P = 0.0056) and TP53 mutations (P = 0.043), and a significant positive correlation with EGFR amplification (P = 0.048). Glioblastoma patients with TERT mutations showed a shorter survival than those without TERT mutations in univariate analysis (median, 9.3 vs. 10.5 months; P = 0.015) and multivariate analysis after adjusting for age and gender (HR 1.38, 95 % CI 1.01–1.88, P = 0.041). However, TERT mutations had no significant impact on patients’ survival in multivariate analysis after further adjusting for other genetic alterations, or when primary and secondary glioblastomas were separately analysed. These results suggest that the prognostic value of TERT mutations for poor survival is largely due to their inverse correlation with IDH1 mutations, which are a significant prognostic marker of better survival in patients with secondary glioblastomas.


  • Top Cited Papers

    The Definition of Primary and Secondary Glioblastoma

    by Hiroko Ohgaki, Paul Kleihues

    Glioblastoma is the most frequent and malignant brain tumor. The vast majority of glioblastomas (∼90%) develop rapidly de novo in elderly patients, without clinical or histologic evidence of a less malignant precursor lesion (primary glioblastomas). Secondary glioblastomas progress from low-grade diffuse astrocytoma or anaplastic astrocytoma. They manifest in younger patients, have a lesser degree of necrosis, are preferentially located in the frontal lobe, and carry a significantly better prognosis. Histologically, primary and secondary glioblastomas are largely indistinguishable, but they differ in their genetic and epigenetic profiles. Decisive genetic signposts of secondary glioblastoma are IDH1 mutations, which are absent in primary glioblastomas and which are associated with a hypermethylation phenotype. IDH1 mutations are the earliest detectable genetic alteration in precursor low-grade diffuse astrocytomas and in oligodendrogliomas, indicating that these tumors are derived from neural precursor cells that differ from those of primary glioblastomas. In this review, we summarize epidemiologic, clinical, histopathologic, genetic, and expression features of primary and secondary glioblastomas and the biologic consequences of IDH1 mutations. We conclude that this genetic alteration is a definitive diagnostic molecular marker of secondary glioblastomas and more reliable and objective than clinical criteria. Despite a similar histologic appearance, primary and secondary glioblastomas are distinct tumor entities that originate from different precursor cells and may require different therapeutic approaches. Clin Cancer Res; 19(4); 764–72. ©2012 AACR.